Loading...
•
Mar 31, 2025
Jazz Pharmaceuticals Q1 2025 Earnings Report
Jazz Pharmaceuticals reported a GAAP net loss of $92.5 million on $898 million in revenue in Q1 2025.
Key Takeaways
Revenue remained flat year-over-year at $898 million, with strong growth in Xywav and Epidiolex offset by declines in oncology products and litigation expenses impacting profitability.
Total revenue was $897.8 million, essentially flat compared to Q1 2024.
Xywav and Epidiolex posted strong year-over-year sales growth of 9% and 10% respectively.
Zepzelca, Rylaze, and Defitelio saw revenue declines due to competitive pressures and protocol changes.
A $172 million litigation settlement significantly impacted GAAP results, resulting in a $92.5 million net loss.
Revenue by Segment
Forward Guidance
Jazz reaffirmed its 2025 revenue guidance of $4.15 to $4.40 billion and updated guidance to reflect the Chimerix acquisition and litigation impacts.
Positive Outlook
- 2025 revenue guidance affirmed at $4.15–$4.40 billion.
- Epidiolex expected to achieve blockbuster status in 2025.
- Strong commercial performance from Xywav and Epidiolex.
- Zepzelca Phase 3 data accepted for presentation at ASCO.
- HERIZON-GEA-01 trial data readout expected in 2H25.
Challenges Ahead
- Significant $172 million litigation expense impacted Q1 results.
- SG&A expenses increased sharply due to legal settlements.
- Rylaze affected by updated pediatric protocols reducing use.
- Zepzelca sales declined due to increased competition.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...